Article Text

other Versions

PDF
Maximal subthalamic beta hypersynchrony of the local field potential in Parkinson's disease is located in the central region of the nucleus
  1. Camille de Solages1,
  2. Bruce C Hill1,
  3. Hong Yu2,
  4. Jaimie M Henderson1,2,
  5. Helen Bronte-Stewart1,2
  1. 1Department of Neurology and Neurological Sciences, Stanford University, California, USA
  2. 2Department of Neurosurgery, Stanford University, California, USA
  1. Correspondence to Dr H Bronte-Stewart, Department of Neurology and Neurological Sciences, Stanford University, 300 Pasteur Dr, Rm A343, Stanford, CA 94305-5327, USA; hbs{at}stanford.edu

Abstract

A pathological marker of Parkinson's disease is the existence of abnormal synchrony of neuronal activity within the beta frequency range (13–35 Hz) in the subthalamic nucleus (STN). Recent studies examining the topography of this rhythm have located beta hypersynchrony in the most dorsal part of the STN. In contrast, this study of the topography of the local field potential beta oscillations in 18 STNs with a 1 mm spatial resolution revealed that the point of maximal beta hypersynchrony was located at 53±24% of the trajectory span from the dorsal to the ventral borders of the STN (corresponding to a 3.0±1.6 mm depth for a 5.9±0.75 mm STN span). This suggests that maximal beta hypersynchrony is located in the central region of the nucleus and that further investigation should be done before using STN spectral profiles as an indicator for guiding placement of deep brain stimulation leads.

Statistics from Altmetric.com

Footnotes

  • Funding This work was supported by grants from the Robert and Ruth Halperin Foundation, the John A Blume Foundation and the Peggy K Cahill Family Research Foundation. The funding sources had no involvement in the study design, in the collection, analysis and interpretation of the data, in the writing of the report or in the decision to submit the paper for publication.

  • Competing interests JMH has a speaker's bureau/honoraria with Medtronic, is on the Scientific Advisory Board of Nevro Corporation and is a consultant for Proteus Biomedical, Inc and NDI Medical. HB-S has received consulting income from Boston Scientific Corporation.

  • Ethics approval This study was conducted with the approval of the Stanford Institutional Review Board.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.